Bob Goeltz bolts Uni­ty Biotech­nol­o­gy to be­come CFO at Ar­cus Bio­sciences; John John­son tapped for his lat­est CEO gig

Bob Goeltz

→ A press re­lease ear­li­er in the week not­ed that Bob Goeltz left his CFO post at Uni­ty Biotech­nol­o­gy “to pur­sue a new op­por­tu­ni­ty.” We now know what that op­por­tu­ni­ty is, join­ing Ter­ry Rosen’s crew at Ar­cus Bio­sciences as the new CFO. A for­mer ex­ec­u­tive di­rec­tor of cor­po­rate de­vel­op­ment at Am­gen, Goeltz was the CFO for Cy­tomX Ther­a­peu­tics be­fore mak­ing the move to an­ti-ag­ing start­up Uni­ty in 2017.

“With the po­ten­tial to have three mol­e­cules in reg­is­tra­tional stud­ies in 2021, a pro­lif­ic dis­cov­ery team and a unique­ly en­abling and nascent al­liance with Gilead, Bob joins Ar­cus at a sem­i­nal in­flec­tion point, with the op­por­tu­ni­ty to make Ar­cus’s vi­sion of cre­at­ing, de­vel­op­ing and com­mer­cial­iz­ing in­no­v­a­tive and cu­ra­tive ther­a­pies for can­cer a re­al­i­ty,” Rosen said in a state­ment.

Lynne Sul­li­van

Mean­while, Uni­ty Biotech­nol­o­gy has se­lect­ed Bio­gen vet Lynne Sul­li­van to re­place Goeltz as their in­ter­im CFO, ef­fec­tive Au­gust 1. Sul­li­van is on the board of di­rec­tors and chairs the au­dit com­mit­tee at Sol­id Bio­sciences, resTOR­bio and Bio­mX. A for­mer CFO at Com­pass Ther­a­peu­tics, she spent more than 10 years at Bio­gen, leav­ing as their SVP of fi­nance.

→ La Jol­la, CA-based biotech CEND Ther­a­peu­tics is mak­ing a change at the top, with David Slack tak­ing over as pres­i­dent and CEO of the can­cer-fo­cused com­pa­ny. A board mem­ber since last year, Slack takes the place of co-found­ing CEO Erk­ki Ru­oslahti, who will still be chair­man and a se­nior ad­vi­sor. The co-founder and ex-CEO of Ki­na­gen, Slack al­so spent 4 years as CBO of Virac­ta Ther­a­peu­tics.

John John­son

John John­son has agreed to be CEO of the rare dis­ease biotech Strong­bridge Bio­phar­ma — the lat­est in a long string of CEO posts. John­son had been Strong­bridge’s chair­man for the last 5 years and brings sub­stan­tial C-suite clout as the ex-CEO of Melin­ta Ther­a­peu­tics and Den­dreon. His record on turn­around at­tempts, though, has been bleak. His oth­er pre­vi­ous lead­er­ship po­si­tions run the gamut in Big Phar­ma, from his tenure at Eli Lil­ly as pres­i­dent of glob­al on­col­o­gy to his time at J&J as com­pa­ny group chair­man, world­wide bio­phar­ma­ceu­ti­cals.

→ Con­sid­er­able per­son­nel moves are play­ing out at Rea­ta, the Texas bio­phar­ma that had to press pause in late March both on their Phase III tri­al for bar­dox­olone in CTD-PAH and on en­roll­ment for the FAL­CON tri­al of bar­dox­olone to treat pa­tients with au­to­so­mal dom­i­nant poly­cys­tic kid­ney dis­ease. First up: Col­in Mey­er has been pro­mot­ed to the new po­si­tion of chief re­search and de­vel­op­ment of­fi­cer and EVP. Mey­er start­ed at Rea­ta in 2003, fill­ing a va­ri­ety of roles be­fore climb­ing to the CMO post in 2013. See­mi Khan suc­ceeds Mey­er as CMO, com­ing off 3 years at Mit­subishi Ten­abe as their de­vel­op­ment team lead. She al­so spent time as the se­nior med­ical di­rec­tor, glob­al R&D for Ab­b­Vie.

Ad­di­tion­al­ly, Kevin John­ston has made his way to Rea­ta as VP and chief tech­ni­cal of­fi­cer. John­ston was most re­cent­ly the VP of sup­ply chain & lo­gis­tics at Tesaro. Fi­nal­ly, An­drea Loewen is now Rea­ta’s VP, glob­al reg­u­la­to­ry af­fairs, bring­ing more than 30 years of reg­u­la­to­ry ex­pe­ri­ence with such com­pa­nies as Bio­gen, Shire and Bax­ter Health­care.

Matthew Os­borne

→ It’s al­so a busy week of ex­ec­u­tive shuf­fling at On­colo­gie as Matthew Os­borne as­sumes the role of CFO, Hagop Yous­soufi­an steps in as in­ter­im CMO, Bill Mc­Don­ald is now VP, CMC, and Ker­ry Culm-Merdek, gets pro­mot­ed to VP of clin­i­cal de­vel­op­ment.

Os­borne leaves a bat­tered Unum Ther­a­peu­tics, where he was their CFO, and be­fore that, he served as head of cor­po­rate af­fairs, com­mu­ni­ca­tions and in­vestor re­la­tions at Voy­ager Ther­a­peu­tics. Yous­soufi­an’s last CMO gig was at BIND Ther­a­peu­tics and he for­mer­ly led ex­per­i­men­tal med­i­cine at Bris­tol My­ers Squibb. Mc­Don­ald most re­cent­ly held the same role of VP, CMC at Con­tra­fect, and be­fore join­ing On­colo­gie, Culm-Merdek was head of clin­i­cal phar­ma­col­o­gy & quan­ti­ta­tive bio­an­a­lyt­ics at Im­muno­Gen.

→ Putting them­selves in the Covid-19 hunt with lenzilum­ab’s po­ten­tial to quash the cy­tokine storms that can af­flict pa­tients, Hu­mani­gen has a trio of new ex­ecs. Dale Chap­pell, who found­ed Black Horse Cap­i­tal, has signed on as the Cal­i­for­nia phar­ma’s CSO. David Tou­s­ley, the ex-CFO at a host of com­pa­nies in­clud­ing Avax Tech­nolo­gies and Dara Bio­sciences, has been named Hu­mani­gen’s chief ac­count­ing of­fi­cer. And Omar Ahmed, a No­var­tis and Roche vet and for­mer glob­al mar­ket­ing leader, im­munol­o­gy at Janssen, has been pro­mot­ed to SVP, clin­i­cal, med­ical and sci­en­tif­ic af­fairs.

Richard Williams

Kin­nate Bio­phar­ma, which jumped in­to the scene last De­cem­ber with a hefty $74.5 mil­lion B round, has en­list­ed Richard Williams as CMO. Williams hails from WuXi NextCODE, where he served as CMO and glob­al head of on­col­o­gy pro­grams. Pre­vi­ous­ly, Williams has served in roles at GRAIL and Puma Biotech­nol­o­gy. In ad­di­tion, the San Diego-based com­pa­ny tapped Pfiz­er vet Robert Ka­nia as SVP, drug dis­cov­ery.

→  To ini­ti­ate busi­ness de­vel­op­ment in the US, French biotech Im­Check Ther­a­peu­tics — which se­cured $53 mil­lion in Se­ries B fi­nanc­ing last De­cem­ber — has named Claude Knopf as CBO. Knopf brings ex­pe­ri­ence from his time spent at Gem­i­ni Ther­a­peu­tics, Pieris Phar­ma­ceu­ti­cals, Bax­ter Bio­science and No­var­tis.

Join­ing forces with J&J in the field of gam­ma delta T cells, Dutch biotech La­va Ther­a­peu­tics has wel­comed Ben­jamin Wino­grad as CMO. Wino­grad was for­mer­ly Cel­gene’s clin­i­cal re­search and de­vel­op­ment ther­a­peu­tic area head for mul­ti­ple myelo­ma.

→ Au­toim­mune dis­ease-fo­cused IM Ther­a­peu­tics has bol­stered its se­nior man­age­ment team with Tom Shea com­ing in as CFO and COO, along with the pro­mo­tion of Sarah Bird to VP, clin­i­cal de­vel­op­ment. Shea was pre­vi­ous­ly the CFO at Im­mu­sanT, which tar­gets celi­ac dis­ease and type 1 di­a­betes, and has al­so been CFO of Al­bireo Phar­ma, Tol­erx and Cu­bist Phar­ma­ceu­ti­cals. Bird was on board at IM Ther­a­peu­tics from its found­ing as di­rec­tor, clin­i­cal de­vel­op­ment, and al­so led glob­al pro­grams when she was a clin­i­cal re­search sci­en­tist at Gilead.

Chris Mora­bito

→ Af­ter Pe­ter Lawrence took the helm as pres­i­dent and CEO in April, Car­du­ri­on Phar­ma­ceu­ti­cals has nabbed Big Phar­ma vet Chris Mora­bito as their new CMO. Mora­bito had held sev­er­al roles at Take­da the last 4 years, and was most re­cent­ly their head of R&D, plas­ma-de­rived ther­a­pies and was a key leader in the Shire ac­qui­si­tion while he was head of pipeline strat­e­gy for glob­al R&D. Be­fore Take­da, Mora­bito spent time at Sanofi and Mer­ck.

Akcea Ther­a­peu­tics, which boast­ed pos­i­tive Phase II da­ta in Jan­u­ary for their drug AKCEA-ANGPTL3-LRx in pa­tients with hy­per­triglyc­eridemia, has ap­point­ed William An­drews as CMO af­ter gain­ing Michael Price as their new CFO in May. Pri­or to his role at Akcea, An­drews had been the CMO at Ac­er Ther­a­peu­tics since 2017. He al­so pro­vid­ed con­sul­ta­tion at Aletheia Bio­sciences and held po­si­tions at Aege­ri­on Phar­ma­ceu­ti­cals.

Richard Shea is re­tir­ing from the CFO post at Syn­dax Phar­ma­ceu­ti­cals, the Waltham, MA com­pa­ny look­ing to shake off last year’s tri­al set­backs in com­bo stud­ies in­volv­ing endi­no­s­tat with Tecen­triq and Baven­cio. Shea has been re­placed by Daphne Kary­das, who gets start­ed Mon­day af­ter be­ing SVP of cor­po­rate fi­nan­cial plan­ning & analy­sis and strat­e­gy at Al­ler­gan. She be­gan her ca­reer as a project chem­i­cal en­gi­neer at Mer­ck be­fore go­ing to Gold­man Sachs as a VP fo­cused on health care.

Michael Amoroso

→ Restart­ing en­roll­ment this week for its piv­otal Phase III study of EB-101 to treat re­ces­sive dy­s­troph­ic epi­der­mol­y­sis bul­losa (RDEB), Abeona Ther­a­peu­tics has brought on Michael Amoroso to be their chief com­mer­cial of­fi­cer. Amoroso was pre­vi­ous­ly SVP and head of world­wide com­mer­cial, cell ther­a­py at Kite. He al­so held sev­er­al roles at Cel­gene and was SVP, Amer­i­c­as for the com­mer­cial on­col­o­gy busi­ness group at Ei­sai.

AVM Biotech­nol­o­gy — whose lead mol­e­cule, AVM0703, has re­ceived FDA per­mis­sion to be­gin clin­i­cal tri­als treat­ing no-op­tion Non-Hodgkin’s Lym­phoma — has tapped Janet Rea as COO. Rea hops aboard the Seat­tle-based biotech with ex­pe­ri­ence from her roles at Im­munex, MDS Phar­ma, AVI Bio­Phar­ma (now Sarep­ta) and Atossa Ther­a­peu­tics among oth­ers.

→ These days, it wouldn’t be Peer Re­view with­out some­thing from No­vavax. The new faces and pro­mo­tions keep on truck­ing as the biotech con­tin­ues to re­tool the team and make news, as they did this week with their $1.6 bil­lion Op­er­a­tion Warp Speed deal. This time it’s Frank Cz­wor­ka get­ting the nod as SVP, glob­al sales and Bri­an Webb get­ting the bump to SVP, man­u­fac­tur­ing. Cz­wor­ka had been VP, glob­al cus­tomer en­gage­ment at US Phar­ma­copeia af­ter 5 years in lead­er­ship roles at Osiris Ther­a­peu­tics. Webb joined No­vavax back in 2014 from GSK, where he was the phar­ma gi­ant’s se­nior man­ag­er, com­mer­cial man­u­fac­tur­ing.

Narinder Singh

→ Cal­i­for­nia-based Aim­mune, which won ap­proval from the FDA in Jan­u­ary with Pal­forzia to treat peanut al­ler­gy, has brought in Am­gen vet Narinder Singh to be EVP of tech­ni­cal op­er­a­tions. Singh left Geno­cea Bio­sciences, where he was SVP, phar­ma­ceu­ti­cal sci­ences and man­u­fac­tur­ing since March 2018. Af­ter 18 years in process de­vel­op­ment at Am­gen, Singh was al­so VP, drug prod­uct de­vel­op­ment & man­u­fac­tur­ing at Mo­men­ta Phar­ma­ceu­ti­cals from 2015-18.

Ab­by Bron­son

→ Less than a month af­ter nam­ing Kirsten Gruis as CMO, Col­orado-based mus­cu­loskele­tal dis­ease biotech Edge­wise Ther­a­peu­tics has made Ab­by Bron­son VP, pa­tient ad­vo­ca­cy and ex­ter­nal in­no­va­tion, a new­ly-cre­at­ed po­si­tion. For 4 years, Bron­son was pre­vi­ous­ly at Par­ent Pro­ject Mus­cu­lar Dy­s­tro­phy (PP­MD) as their SVP of re­search strat­e­gy. She’s al­so been in the clin­i­cal in­no­va­tion di­vi­sion at NIH’s Cen­ter for Ad­vanc­ing Trans­la­tion­al Sci­ences.

Organon & Co., Mer­ck’s in­tend­ed spin­off of its women’s health, lega­cy brands and biosim­i­lars busi­ness­es, has named Deb­o­rah Tel­man their gen­er­al coun­sel. An Ab­bott vet, Tel­man jumps to Organon from Sor­ren­to Ther­a­peu­tics, where she was SVP, gen­er­al coun­sel & cor­po­rate Sec­re­tary.

Denelle Wayn­ick

Denelle Wayn­ick is head­ed to MyoKar­dia, which re­vealed stel­lar Phase III da­ta in May with its HCM drug mava­camten, as gen­er­al coun­sel and cor­po­rate sec­re­tary. She re­places the re­tir­ing Cyn­thia Ladd, who had been with the South San Fran­cis­co bio­phar­ma since Jan­u­ary 2018. Wayn­ick was pre­vi­ous­ly UCB’s US gen­er­al coun­sel & head of glob­al en­ter­prise risk man­age­ment.

→ Back in ear­ly April, we not­ed the pro­mo­tion of Jesse Mc­Cool to CEO of Ok­la­homa City-based CD­MO Cy­to­vance Bi­o­log­ics. This week, they’ve en­list­ed Yuk Chun Chiu as VP of man­u­fac­tur­ing op­er­a­tions. Chiu has been as­so­ci­at­ed with some of the biggest names in the in­dus­try: Be­fore mov­ing on to Cy­to­vance, he was As­traZeneca’s di­rec­tor of man­u­fac­tur­ing and en­gi­neer­ing, and he’s al­so been group head of process an­a­lyt­i­cal tech­nol­o­gy at Bay­er.

Nor­bert Bischof­berg­er’s bio­phar­ma Kro­nos Bio, fo­cused on mod­u­lat­ing tran­scrip­tion fac­tors in can­cer, has re­cruit­ed Jen­nifer Nichol­son as VP, reg­u­la­to­ry af­fairs. Nichol­son had been with Ac­er­ta (ac­quired by As­traZeneca) as their head of reg­u­la­to­ry, specif­i­cal­ly the glob­al reg­u­la­to­ry lead for Calquence. She kicked off her reg­u­la­to­ry ca­reer at Genen­tech, where she re­mained for 11 years, even­tu­al­ly mov­ing on to roles at Jazz Phar­ma­ceu­ti­cals and Onyx Phar­ma­ceu­ti­cals.

Stephen Squin­to

→ San An­to­nio-based bioAffin­i­ty Tech­nolo­gies has named Alex­ion co-founder Stephen Squin­to vice chair­man of their board of di­rec­tors, and the can­cer di­ag­nos­tics and ther­a­peu­tics com­pa­ny al­so tapped David Elzi as VP of re­search. Squin­to is cur­rent­ly an ex­ec­u­tive part­ner with Or­biMed Health­care Fund Man­age­ment, while Elzi joined bioAffin­i­ty in 2016 as their di­rec­tor of ba­sic re­search.

→ Say­ing he wants to chan­nel his en­er­gy in­to his work at Cel­lec­tis, An­dré Chouli­ka is re­tir­ing from the board of di­rec­tors at Ca­lyxt (for­mer­ly Cel­lec­tis Plant Sci­ences). At the same time, the board named Lau­rent Arthaud as a Cel­lec­tis des­ig­nat­ed di­rec­tor. Chouli­ka co-found­ed and had chaired Ca­lyxt since 2010.

Ed­win Moses

Ed­win Moses, who as­sumed the chair­man­ship of Achilles Ther­a­peu­tics in De­cem­ber 2018, will be chair­man of the board at French hear­ing loss-fo­cused bio­phar­ma Sen­so­ri­on, suc­ceed­ing Patrick Lan­glois. Cur­rent­ly the chair­man of 2 oth­er com­pa­nies, Avan­tium and Lab­Ge­nius, Moses was the long­time CEO of Abl­ynx.

Au­dentes Ther­a­peu­tics EVP and chief op­er­at­ing of­fi­cer Thomas Soloway has hopped on the board of di­rec­tors at mi­graine-fo­cused South San Fran­cis­co biotech Sat­suma Phar­ma­ceu­ti­cals. Soloway is for­mer­ly the SVP and CFO of As­cendis Phar­ma A/S and the EVP and COO of Tran­scept Phar­ma­ceu­ti­cals.

Michael Shep­ard, one of the 3 in­ven­tors of Her­ceptin, has signed on to the board of di­rec­tors at Pa­cif­ic North­west biotech Pas­cal Bio­sciences. Shep­ard start­ed his ca­reer in 1980 at Genen­tech and has al­so been VP and CSO at Halozyme Ther­a­peu­tics.

→ Af­ter hav­ing their NASH drug elafi­bra­nor fail in a Phase III to dis­tin­guish it­self from place­bo, Gen­fit has wel­comed for­mer J&J ex­ec Kather­ine Kalin and Eli Lil­ly vet Er­ic Ba­clet to its board of di­rec­tors.

→ Ex-Cel­gene ex­ec George Golumbes­ki has joined the board of di­rec­tors at Nor­wood, MA-based biotech Cor­bus Phar­ma­ceu­ti­cals. In ad­di­tion to his time at Cel­gene, Golumbes­ki held roles at No­var­tis, Elan Phar­ma­ceu­ti­cals and Schwarz Phar­ma.

Lorenz Mayr

→ Up­start cell con­ver­sion biotech Mo­gri­fy has made the ad­di­tion of Lorenz Mayr to its board of di­rec­tors. Most re­cent­ly, Mayr served as chief tech­ni­cal of­fi­cer at GE Health­care Life Sci­ences and has had stints at As­traZeneca and No­var­tis.

→ South San Fran­cis­co cell ther­a­py play­er Al­lo­gene has added Thomas Gajew­s­ki and Stephan Grupp to their sci­en­tif­ic ad­vi­so­ry board. Gajew­s­ki is the Ab­b­Vie Foun­da­tion Pro­fes­sor in Can­cer Im­munother­a­py at the Uni­ver­si­ty of Chica­go, while Grupp is the di­rec­tor of the Can­cer Im­munother­a­py Pro­gram, di­rec­tor of trans­la­tion­al re­search for the Cen­ter for Child­hood Can­cer Re­search and med­ical di­rec­tor of the Stem Cell Lab­o­ra­to­ry at Chil­dren’s Hos­pi­tal of Philadel­phia.

→ Col­lab­o­rat­ing with Janssen Phar­ma­ceu­ti­cals to pro­pel its be.well plat­form for­ward, Alveo Tech­nolo­gies has cho­sen Justin Steb­bing for their sci­en­tif­ic ad­vi­so­ry board, join­ing fel­low mem­bers George Church, John DeVin­cen­zo and Poo­ja Goel. Steb­bing is a pro­fes­sor of can­cer med­i­cine and on­col­o­gy and con­sul­tant on­col­o­gist at Im­pe­r­i­al Col­lege Lon­don.

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The slate of products we’re offering here at Endpoints is continuing to grow, and it’s not just limited to editorial. If you haven’t, do visit your reader profile to see if there are any other weekly newsletters you’re interested in — as each comes with its own exclusive content. And don’t miss the publisher’s note from Arsalan Arif on Endpoints Studio, our latest avenue for advertising on Endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Usama Malik

Ex-Im­munomedics CFO charged with in­sid­er trad­ing, faces up to 20 years in prison af­ter al­leged­ly tip­ping off girl­friend and rel­a­tives of a PhI­II suc­cess

The former CFO of Immunomedics, who helped steer the company to its $21 billion buyout by Gilead last year, has been charged with insider trading, the Department of Justice announced Thursday.

Usama Malik tipped off his then-girlfriend and four others that a Phase III study for Trodelvy would be stopped early four days before Immunomedics publicly announced the result in April 2020, DoJ alleged in its complaint. The individuals then purchased Immunomedics shares, selling them after the news broke and Immunomedics’ stock price doubled.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Merck's new antiviral molnupiravir (Quality Stock Arts / Shutterstock)

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

After South African scientists reported a new Covid-19 variant — dubbed Omicron by the WHO — scientists became concerned about how effective vaccines and monoclonal antibodies might be against it, which has more than 30 mutations in the spike protein.

“I think it is super worrisome,” Dartmouth professor and Adagio co-founder and CEO Tillman Gerngross told Endpoints News this weekend. Moderna CEO Stéphane Bancel echoed similar concerns, telling the Financial Times that experts warned him, “This is not going to be good.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

In­cor­po­rat­ing Ex­ter­nal Da­ta in­to Clin­i­cal Tri­als: Com­par­ing Dig­i­tal Twins to Ex­ter­nal Con­trol Arms

Most drug development professionals are familiar with the nerve-racking wait for the read-out of a large trial. If it’s negative, is the investigational therapy ineffective? Or could the failure result from an unforeseen flaw in the design or execution of the protocol, rather than a lack of efficacy? The team could spend weeks analyzing data, but a definitive answer may be elusive due to insufficient power for such analyses in the already completed trial. These problems are only made worse if the trial had lower enrollment, or higher dropout than expected due to an unanticipated event like COVID-19. And if a trial is negative, the next one is likely to be larger and more costly — if it happens at all.

Ab­b­Vie tacks on a new warn­ing to Rin­voq la­bel as safe­ty frets crimp JAK class

The safety problems that continue to plague the JAK class as new data highlight some severe side effects are casting a large shadow over AbbVie’s Rinvoq.

As a result of a recent readout highlighting major adverse cardiac events (MACE), malignancy, mortality and thrombosis with Xeljanz a couple of months ago, AbbVie put out a notice late Friday afternoon that it is adding the new class risks to its label for their rival drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select more effective and safer drug candidates in the future.

The combined companies will now serve a wider range of drug research and development scientists, according to Albert Li, who founded IVAL in 2004 and is set to join the Discovery leadership team as the CSO of pharmacology and toxicology.

Pfiz­er, Am­gen and Janssen seek fur­ther clar­i­ty on FDA's new ben­e­fit-risk guid­ance

Three top biopharma companies are seeking more details from the FDA on how the agency conducts its benefit-risk assessments for new drugs and biologics.

While Pfizer, Amgen and Janssen praised the agency for further spelling out its thinking on the subject in a new draft guidance, including a discussion of patient experience data as part of the assessment, the companies said the FDA could’ve included more specifics in the 20-page draft document.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Re­searchers move clos­er to de­ci­pher­ing blood clots from As­traZeneca, J&J's Covid-19 vac­cines

Researchers may be nearing an answer for the mysterious and life-threatening blood clots that appeared on very rare occasions in people who received the J&J or AstraZeneca Covid-19 vaccine.

The new work builds on an early hypothesis researchers in Norway put forward last spring, when the cases first cropped up. They proposed the events were similar to blood clots that can occur in a small subset of patients who receive heparin, one of the most commonly used blood thinners.